the apparel space could stand to benefit from the rise of weight-loss drugs, says jim cramer
Published 9 months ago • 10K plays • Length 10:44Download video MP4
Download video MP3
Similar videos
-
2:49
we should start looking at stocks that benefit from weight-loss drugs, says jim cramer
-
4:04
jim cramer takes a closer look at stocks that could be impacted by weight-loss drugs
-
4:21
eli lilly's weight-loss drug could be the best selling drug of all time, says jim cramer
-
3:45
are weight loss drugs to blame for a decline in gym sign-ups? jim cramer investigates
-
2:49
jim cramer explains why he favors eli lilly in the weight loss drug space
-
12:06
investors are forgetting that the economy has to weaken for the fed to cut rates, says jim cramer
-
9:54
jim cramer's takeaway from monday's market: 'removal of uncertainty'
-
2:27
cramer’s mad dash: servicenow
-
3:56
jim cramer: charts suggest near-term market pain may be over, but don't expect a big rally
-
4:35
jim cramer weighs the market impact of eli lilly and novo nordisk's weight loss drugs
-
2:55
eli lilly's experimental obesity drug could be 'revolutionary,' says jim cramer
-
10:13
biggest indicators for weight loss drugs are yet to come, says jim cramer
-
2:40
jim cramer dissects how glp-1 drugs are disrupting the entire healthcare industry
-
2:57
cramer says the growing popularity of weight loss drugs brings new
-
6:17
fmr. fda commissioner dr. scott gottlieb on diabetes drugs: overall it's being used appropriately
-
11:26
jim cramer takes a closer look at stock market effects from diabetic and weight-loss drugs
-
4:51
weight-loss drugs can be effective but must be used appropriately, says dr. scott gottlieb
-
1:55
cramer: the market sell-off is a seasonal self-fulfilling prophecy
-
6:01
what other industries could weight loss drugs disrupt?
-
2:39
jim cramer: shares of bath & body works are a 'steal'
-
3:34
jim cramer: buy a stock that has come down so much you can't believe it
-
6:29
dr. scott gottlieb on weight loss drugs side effects, eli lilly's direct-to-consumer bet